Non Hodgkin Lymphoma Clinical Trial
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin’s Lymphoma
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving rituximab together with vaccine therapy and GM-CSF may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with vaccine therapy and GM-CSF works in treating patients with indolent B-cell non-Hodgkin's lymphoma.
Full Description
OBJECTIVES:
Determine the efficacy of immunotherapy comprising rituximab, autologous immunoglobulin idiotype-KLH conjugate vaccine (FavIdâ„¢), and sargramostim (GM-CSF), in terms of response rate (partial and complete) and event-free survival, in patients with indolent B-cell non-Hodgkin's lymphoma.
Determine the safety of this regimen in these patients.
Evaluate development of an immune response in patients treated with this regimen.
OUTLINE: This is an open-label, multicenter study.
Induction therapy: Patients receive rituximab IV over 2-4 hours once weekly for 4 weeks. Patients are evaluated for response at month 3. Patients with responding or stable disease proceed to maintenance therapy. Patients with progressive disease are removed from study.
Maintenance therapy: Patients receive rituximab as in induction therapy in months 7, 13, and 19. Patients also receive autologous immunoglobulin idiotype-KLH conjugate vaccine (FavIdâ„¢) subcutaneously (SC) once on day 1 and sargramostim (GM-CSF) SC once daily on days 1-4 in months 4-6, 8-11, 14, 16, 18, 20, 22, and 24. Patients with continued response after completing 2 years of therapy may continue to receive FavIdâ„¢ and GM-CSF once every 3 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes:
Grade 1 or 2 follicular lymphoma
Tumor must be accessible to biopsy or biopsy material available for preparation of autologous immunoglobulin idiotype-KLH conjugate vaccine (FavIdâ„¢)
Measurable or evaluable disease after node biopsy
No mantle cell, marginal zone, MALT-type, small lymphocytic, or grade 3 follicular (follicular large cell) lymphoma
No CNS involvement with lymphoma
PATIENT CHARACTERISTICS:
Performance status
ECOG 0-2
Life expectancy
Not specified
Hematopoietic
Platelet count > 100,000/mm^3
WBC ≥ 3,000/mm^3
Hepatic
AST and ALT ≤ 2 times upper limit of normal
Bilirubin ≤ 2 mg/dL
Renal
Creatinine ≤ 1.5 mg/dL
Other
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 30 days after completion of study treatment
HIV negative
No other medical or psychiatric disease that would preclude study compliance
No other malignancy (active or treated) within the past 5 years
PRIOR CONCURRENT THERAPY:
Radiotherapy
Prior local radiotherapy allowed
Other
No other prior anticancer therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Nashville Tennessee, 37203, United States More Info
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.